Biotech entity

Big Pharma

industry

All 1 tracked stories fall under one category: pharma. Big Pharma is most often covered alongside AMR Action Fund, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Big Pharma, all published on March 10, 2026.

Last mentioned: Mar 10, 2026

Entity pulse

Recent coverage · Big Pharma

1 story
7 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Big Pharma

All 1 tracked stories fall under one category: pharma. Big Pharma is most often covered alongside AMR Action Fund, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Big Pharma, all published on March 10, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Big Pharma. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. STAT Analysis Released

    Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.

  2. Small Biotech Crisis

    A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.

  3. Market Exit Acceleration

    Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.

  4. Baseline Period

    Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.

Stories mentioning Big Pharma 1

Pharma Negative

Big Pharma’s Antibiotic Pipeline Shrinks 35% as Market Failures Deepen

A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.

2 sources

Big Pharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.